The Instrument and Test Strips are integrated with several quality control checks to ensure the Instrument and Test are functioning correctly for every test run.

The workflow process is comprised of a simple sample prep along with step-by-step guidance of the Instrument to report a patient result in under 12 minutes from sample application.

The use of a LumiraDx SARS-CoV-2 Ag Test on the LumiraDx Instruments will enable the physician to verify infection quickly, begin proper treatment and to initiate isolation precautions helping prevent further spread of infection.

• Easy to implement in point-of-care settings
• Clinical performance
  • 97.6% positive percent agreement
  • 96.6% negative percent agreement
• Analytical performance with a limit of detection of 32 TCID₅₀/mL
• RT-PCR comparable results within 12 days of onset of symptoms

In clinical studies, the LumiraDx SARS-CoV-2 antigen test ( Unique MicroFluidic Strip Technology whereas most other brands using very OLD & Traditional “ Laminar( Lateral ) Flow Technology”  )  demonstrated 97.6% positive agreement versus RT-PCR in patients tested within 12 days of the onset of symptoms, to enable the physician to verify infection quickly, begin proper treatment and to initiate isolation precautions helping prevent further spread of infection.